FGF21 deficiency has been proved to promote the development of inflammation, intrahepatic steatosis, hepatocyte damage, and fibrosis, whereas FGF21 analogs have potentially been introduced to inhibit nonalcoholic steatohepatitis (NASH) by weakening these processes [17]. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.